TSE:4503Pharmaceuticals
Astellas Pharma (TSE:4503) Profit Margins Double, Challenging Bearish Narratives on Earnings Quality
Astellas Pharma (TSE:4503) delivered net profit margins of 6.2%, doubling from 3.1% last year, while posting a 128.1% surge in profit growth over the past year compared to a five-year average decline of 24% per year. Despite this impressive profitability turnaround, revenue is forecast to decline 4.5% per year over the next three years, and the latest financial period included a one-off loss of ¥169.5 billion that has weighed on trailing results. The stock currently trades at ¥1,613.5, below...